Co-branded TaurX's new drug Genting expects approval as soon as possible

In response to questions at a press conference on Thursday, Genting Chairman and CEO Tan Sri Lam Cathay said that Genting is only a small operator in the pharmaceutical field, not comparable to many pharmaceutical giants, but the company is determined to bring cheaper and more effective drugs to the world.

“In addition to its core business, Genting is also undertaking some new projects, and TaurX's new drug is one of them. We expect good news soon in terms of official approval of this new drug.”

Genting President, Chief Operating Officer and Executive Director Dato' Sri Chan Kwang-han pointed out that many activities are currently underway, and the official approval process for new drugs is underway, particularly the UK Medicines and Healthcare Products Regulatory Authority (MHRA).

“As for the FDA, we are awaiting their feedback and the process is still ongoing.”

Chen Guanghan stressed that only the official agency knows what stage the approval process for the new TaurX drug has reached; everything has to be decided by the other party.

According to clinical test results announced in March of this year, TaurX said that its new drug has lasting effects in fighting dementia and has no sequelae of cerebral hemorrhage. Compared with other drugs for dementia, the price is also lower.